A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) and Intolerant to Entecavir

NCT04034368 | Unknown Phase 4 FDA Drug

• 1 other identifier: ISR-CN-18-10478
• Study Type: interventional
• Target: 8
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a multicenter, single arm, open label, historical control pilot Study to the antiviral efficacy and safety of Suboptimal Responders to Entecavir Switching to TAF Treatment at week 48 (investigate the rates of complete virological response on switching to TAF in patients with Suboptimal response or ETV intolerance to standard ETV= 0.5 mg monotherapy).

Conditions

HBV

Outcome Measures

Primary Outcomes (1)

• Main efficacy endpoint

  The primary efficacy endpoint is the proportion of subjects with plasma HBV DNA levels below 20 IU/ml at Week 48.

  Week 48

Secondary Outcomes (7)

• Key secondary efficacy endpoint

  Week 24

• Key secondary efficacy endpoint

  Week 48

• Key secondary efficacy endpoint

  Week 24 and Week 48

• Key secondary efficacy endpoint

  Week 48

• Key secondary efficacy endpoint

  Week 48

Study Arms (1)

Experimental Arm

EXPERIMENTAL

Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；

Drug: Tenofovir Alafenamide (TAF)

Interventions

Tenofovir Alafenamide (TAF) DRUG

Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；

Experimental Arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures;
• Male and female subjects,18 years of age and older, based on the date of the screening visit;
• Suboptimal Responders to Entecavir (defined as CHB patients treated with at least 12 months of ETV 0.5mg QD with prior suboptimal response viral load still detectable at week 48).
• ETV intolerance population (defined as unwilling or poor adherence to administer ETV in fasting food, renal impairment with ETV dosage adjustment required, pts with other unidentified reasons willing to switch, etc);
• Screening serum ALT level ≤ 10 × ULN;
• Normal ECG (or if abnormal, determined by the Investigator not to be clinically significant);
• Must be willing and able to comply with all study requirements.

You may not qualify if:

• Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study;
• Co-infection with HCV, HIV, or HDV;
• Any history of, or current evidence of, clinical hepatic decompensation (i.e., moderate-severe ascites, encephalopathy or variceal hemorrhage);
• Evidence of hepatocellular carcinoma (e.g. as evidenced by recent imaging);
• Abnormal hematological and biochemical parameters, including: Hemoglobin \< 10 g/dl, Absolute neutrophil count \< 0.75×109/L, Platelets ≤ 50×109/L, AST or ALT \> 10 × ULN, Total bilirubin \> 2.5 × ULN, Albumin \< 3.0 g/dl, INR \> 1.5 × ULN;
• Received solid organ or bone marrow transplant;
• Recent history of pancreatitis (within 24 weeks prior to the first dose of study medication);
• Evidence of other autoimmune or metabolic liver diseases (except non-alcoholic fatty liver disease);
• Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of the investigator;
• Malignancy within the 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection(basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible;
• Known hypersensitivity to study drugs, metabolites, or formulation excipients;
• Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance;
• Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.

Sponsors & Collaborators

• The First Hospital of Jilin University: lead

MeSH Terms

Interventions

tenofovir alafenamide

Central Study Contacts

Yanhang Gao

CONTACT

15804303019; 15804303019@qq.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: July 24, 2019
• First Posted: July 26, 2019
• Study Start: August 1, 2019
• Primary Completion: June 1, 2021
• Study Completion: June 1, 2021
• Last Updated: July 26, 2019

Record last verified: 2019-07

Data Sharing

• IPD Sharing: Will not share